Skip to main content

BioCommunique Article

Bringing you the latest financial and strategic news from top leaders in life science over the past two weeks.

GSK Buys Sitari; BI and Lupin Launch $700M Collab; 10X Genomics Plans $362M IPO

  • 2019-09-12T20:48:00.000+0000
  • California
  • Author: Lauren Panetta

9/11/19 – Endpoints
Merck KGaA touts FDA 'breakthrough' status, blockbuster potential in bid to woo investors

9/11/19 – FierceBiotech
Pfizer Oncology hires MD Anderson researcher

9/10/19 – The San Diego Union-Tribune
Progress in celiac disease leads GSK to buy San Diego’s Sitari

9/9/19 – FierceBiotech
Axonics nets FDA approval for its rechargeable sacral neuromodulation implant

9/9/19 – FierceBiotech
Lilly's RET drug hits 68% ORR in lung cancer

9/6/19 – The San Diego Union-Tribune
From rock/paper/scissors to new cancer-fighting concept from UCSD scientists

9/6/19 – FierceBiotech
Abbott launches large trial of its tricuspid valve repair device

9/5/19 – BridgeBio
BridgeBio Pharma expands its research into neuromuscular disease to include Limb-Girdle Muscular Dystrophy Type 2 (LGMD2i) with new subsidiary ML Bio Solutions

9/5/19 – Endpoints
Global Blood Therapeutics buoyed by good news from FDA; Cigna to help cover pricey therapies

9/5/19 – FierceBiotech
Novartis, IFM Due ink R&D deal—with $840M buyout option

9/4/19 – GEN
Boehringer Ingelheim, Lupin Launch $700M+ Cancer Therapy Collaboration Targeting KRAS

9/4/19 – FierceBiotech
Bristol-Myers teams with BioMotiv to build and buy biotechs

9/3/19 – Cidara Therapeutics
Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin

9/3/19 – GEN
10x Genomics Plans Up-to-$362M IPO, Potentially Triple Its Original Offering

9/3/19 – Xconomy
Vertex Bets $950M on Semma and a Stem Cell Therapy for Diabetes

9/2/19 – Novartis
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings

8/28/19 – Xconomy
Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight

8/27/19 – FierceBiotech
GSK licenses Ionis' midphase hepatitis B program for $25M

8/26/19 – FierceBiotech
NuVasive brings porous titanium implants to its TLIF offerings